GU Cancers Symposium 2011: ASCO ASTRO SUO - Immune targeting in prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Options for immunotherapy include using the patient’s own antigen presenting cells plus a tumor antigen. A viral vector containing transgenes for tumor antigen and immunstimulatory molecules is another option. Sipuleucel-T (Provenge) is based upon a laboratory stimulated leukapheresis product from the patient. There is a 4.1-month survival benefit for OS in patients treated with Provenge. At the NCI they are focusing on off the shelf vaccines that can be widely evaluated. They are using co-stimulatory molecules, one called TRICOM, to stimulate an immune response. A phase II trial of Prosvac showed no change in progression free survival, but an improvement in OS of 8.5 months. A planned phase III trial will start this year evaluating PSA-TRICOM. One benefit in the consideration of vaccines in combination therapy is that they have little toxicity. Radiation and chemotherapy can alter tumor phenotype and sensitize them to T-cell killing. For example, in combination with samarium, PSA-TRICOM improves survival.

A final benefit, Dr. Schlom noted, was that immunotherapy is longer lasting than chemotherapy or targeted therapies.

Presented by Jeffrey Schlom, PhD at the 2011 Genitourinary Cancers Symposium, General Session III: Translational Science Session: New Targets for Prostate Cancer Therapy - February 17-19, 2011 - Orlando World Center Marriott, Orlando, Florida USA


The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the GU Cancers Symposium, ASCO, ASTRO, or SUO




email news signup